▶ 調査レポート

フォンビルブランド病治療の世界市場

• 英文タイトル:von Willebrand Disease Treatment Market (Disease Type: Type 1 von Willebrand Disease, Type 2 von Willebrand Disease, Type 3 von Willebrand Disease, and Acquired von Willebrand Disease; Drug: Desmopressin, Clot-stabilizing Medications, Replacement Therapies, Contraceptives, and Others; Route of Administration: Oral, Injection, and Other; Gender: Men and Women; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027
• レポートコード:TPM-AG026
• 出版社/出版日:Transparency Market Research / 2019年7月
• レポート形態:英文、PDF、241ページ
• 納品方法:Eメール
• 産業分類:製薬
• 販売価格(消費税別)
  Single User¥625,860 (USD5,795)▷ お問い合わせ
  Multi User¥949,860 (USD8,795)▷ お問い合わせ
  Global Site License¥1,273,860 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、フォンビルブランド病治療の世界市場について調べ、フォンビルブランド病治療の世界市場規模、市場動向、市場シェア、市場環境、市場予測、疾患タイプ別(タイプ1フォンウィルブランド病、タイプ2フォンウィルブランド病、タイプ3フォンウィルブランド病、および後天性フォンウィルブランド病)分析、薬物別(デスモプレシン、血餅安定化薬、補充療法、避妊薬、その他)分析、投与経路別(経口、注射、その他)分析、性別(男性、女性)分析、関連企業情報などをまとめました。
・フォンビルブランド病治療の市場概要
・フォンビルブランド病治療の市場動向
・フォンビルブランド病治療の世界市場規模・予測
・フォンビルブランド病治療市場:疾患タイプ別(タイプ1フォンウィルブランド病、タイプ2フォンウィルブランド病、タイプ3フォンウィルブランド病、および後天性フォンウィルブランド病)
・フォンビルブランド病治療市場:薬物別(デスモプレシン、血餅安定化薬、補充療法、避妊薬、その他)
・フォンビルブランド病治療市場:薬物別(デスモプレシン、血餅安定化薬、補充療法、避妊薬、その他)
・フォンビルブランド病治療市場:性別(男性、女性)
・地域別分析(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)
・競争環境・関連企業分析

TMR’s recent report on the von Willebrand disease treatment market offers readers an overall market overview with the help of comprehensive analysis of the global market. The TMR study on the von Willebrand disease treatment market evaluates the market with respect to the historical and current market scenario, and provides a forecast for the period of 2019-2027. Report audiences are able to make key business decisions with the help of the findings and exclusive von Willebrand disease treatment market insights included in the report. TMR’s report also provides an assessment of the key von Willebrand disease treatment market dynamics that are likely to impact the market in the future. The report also offers a thorough understanding of the key industry trends and developments made by von Willebrand disease treatment market players. The TMR report is divided into vital sections, which allows readers to gain an individual understanding of the von Willebrand disease treatment market.

Key Questions Answered in the Report

What are key trends that are likely to influence the von Willebrand disease treatment market in the coming five years?
Which disease type is expected to prevail in the von Willebrand disease treatment market?
How much will the von Willebrand disease treatment market value in the year 2027?
Which regions are likely to generate major sales opportunities for von Willebrand disease treatment market players?
What are the key developments carried out by leading von Willebrand disease treatment market contributors?
The first section in the study on the von Willebrand disease treatment market includes a preface that provides a brief market overview, including definition and scope of the market. This chapter highlights the key research objectives that allow readers to gain a concise market understanding. Following this section is the executive summary that sheds light on the von Willebrand disease treatment market aspects covered in the report. The next chapter in the von Willebrand disease treatment market report is the market overview, which offers a glance into the market in terms of key von Willebrand disease treatment market dynamics such as drivers, opportunistic avenues, and restraining factors.

The next chapter offers an outlook of the global von Willebrand disease treatment market analysis and forecast in terms of volume and value. Following this overview is the market outlook in terms of the regulatory scenario in different regions, along with the global reimbursement scenario. Following this is a detailed segmentation analysis of the von Willebrand disease treatment market. The evaluation includes bifurcation on the basis of disease type, drug, route of administration, gender, distribution channel, and region. The evaluation of key segments in the von Willebrand disease treatment market and inclusion of year-on-year growth projection, along with basis point share analysis, further helps clients identify lucrative avenues.

The TMR study on the von Willebrand disease treatment market offers an assessment of the geographical landscape of the market. The regional assessment helps market players make strategic decisions pertaining to their expansion strategies and investments. Segment-wise and country-level assessment of individual regions helps audiences of the von Willebrand disease treatment market study evaluate the potential of the market. Backed by year-on-year growth projections, and global value and volume share, this section is a significant part of the report on the von Willebrand disease treatment market.

The study on the von Willebrand disease treatment market provides a holistic competitive assessment, providing details of leading market players. This sections highlights the nature of the von Willebrand disease treatment market with the help of the market share held by leading, emerging, and new players. The dashboard view of the competitive landscape in the von Willebrand disease treatment market report allows readers to assess the strategies implemented by players and their performance in the von Willebrand disease treatment market, featuring focus areas of the von Willebrand disease treatment market players. The competitive structure of prominent players in the von Willebrand disease treatment market is also discussed in the study.

Research Methodology

The TMR report on the von Willebrand disease treatment market is based on an in-depth evaluation of the market, including comprehensive primary and secondary research. Detailed evaluation of the von Willebrand disease treatment market in terms of competitive landscape is backed by individual-level analysis of various aspects related to the market. An evaluation of the historical and current market scenario for von Willebrand disease treatment, focusing on key market segments, major regions, and market dynamics, along with other qualitative inputs, helps TMR analysts derive vital predictions and offer a forecast analysis for the von Willebrand disease treatment market. Report audiences can access the von Willebrand disease treatment market study to gain a forecasted market assessment for the period of 2019–2027.

レポート目次

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global von Willebrand Disease Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Disease Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global von Willebrand Disease Treatment Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Clinical Trial Analysis of von Willebrand Disease
5.2. Disease Prevalence Rate Globally with key countries
5.3. Pipeline Analysis of von Willebrand Disease
5.4. Key Industrial Events (Licensing & Acquisitions)
5.5. Average Annual Cost of Therapy
5.6. Reimbursement Scenario, by Region/globally
5.7. Disease Overview
5.8. Future Prospects Assessment
5.9. Regulatory Scenario, by Region/globally
5.10. Treatment Options for Women with Menorrhagia in von Willebrand Disease
6. Global von Willebrand Disease Treatment Market Analysis and Forecast, by Disease Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Disease Type, 2017–2027
6.3.1. Type 1 vWD
6.3.2. Type 2 vWD
6.3.3. Type 3 vWD
6.3.4. Acquired vWD
6.4. Market Attractiveness, by Disease Type
7. Global von Willebrand Disease Treatment Market Analysis and Forecast, by Drug
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Drug, 2017–2027
7.3.1. Desmopressin
7.3.2. Clot-stabilizing Medications
7.3.3. Replacement Therapies
7.3.4. Contraceptives
7.3.5. Others
7.4. Market Attractiveness, by Drug
8. Global von Willebrand Disease Treatment Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2017–2027
8.3.1. Oral
8.3.2. Injection
8.3.3. Other
8.4. Market Attractiveness, by Route of Administration
9. Global von Willebrand Disease Treatment Market Analysis and Forecast, by Gender
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Gender, 2017–2027
9.3.1. Men
9.3.2. Women
9.4. Market Attractiveness, by Gender
10. Global von Willebrand Disease Treatment Market Analysis and Forecast, by Distribution Channel
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast, by Distribution Channel, 2017–2027
10.3.1. Online Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Hospital Pharmacies
10.4. Market Attractiveness, by Distribution Channel
11. Global von Willebrand Disease Treatment Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness, by Country/Region
12. North America von Willebrand Disease Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Disease Type, 2017–2027
12.2.1. Type 1 vWD
12.2.2. Type 2 vWD
12.2.3. Type 3 vWD
12.2.4. Acquired vWD
12.3. Market Value Forecast, by Drug, 2017–2027
12.3.1. Desmopressin
12.3.2. Clot-stabilizing Medications
12.3.3. Replacement Therapies
12.3.4. Contraceptives
12.3.5. Others
12.4. Market Value Forecast, by Route of Administration, 2017–2027
12.4.1. Oral
12.4.2. Injection
12.4.3. Other
12.5. Market Value Forecast, by Gender, 2017–2027
12.5.1. Men
12.5.2. Women
12.6. Market Value Forecast, by Distribution Channel, 2017–2027
12.6.1. Online Pharmacies
12.6.2. Retail Pharmacies
12.6.3. Hospital Pharmacies
12.7. Market Value Forecast, by Country, 2017–2027
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Disease Type
12.8.2. By Drug
12.8.3. By Route of Administration
12.8.4. By Gender
12.8.5. By Distribution Channel
12.8.6. By Country
13. Europe von Willebrand Disease Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Disease Type, 2017–2027
13.2.1. Type 1 vWD
13.2.2. Type 2 vWD
13.2.3. Type 3 vWD
13.2.4. Acquired vWD
13.3. Market Value Forecast, by Drug, 2017–2027
13.3.1. Desmopressin
13.3.2. Clot-stabilizing Medications
13.3.3. Replacement Therapies
13.3.4. Contraceptives
13.3.5. Others
13.4. Market Value Forecast, by Route of Administration, 2017–2027
13.4.1. Oral
13.4.2. Injection
13.4.3. Other
13.5. Market Value Forecast, by Gender, 2017–2027
13.5.1. Men
13.5.2. Women
13.6. Market Value Forecast, by Distribution Channel, 2017–2027
13.6.1. Online Pharmacies
13.6.2. Retail Pharmacies
13.6.3. Hospital Pharmacies
13.7. Market Value Forecast, by Country/Sub-region, 2017–2027
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Disease Type
13.8.2. By Drug
13.8.3. By Route of Administration
13.8.4. By Gender
13.8.5. By Distribution Channel
13.8.6. By Country/Sub-region
14. Asia Pacific von Willebrand Disease Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Disease Type, 2017–2027
14.2.1. Type 1 vWD
14.2.2. Type 2 vWD
14.2.3. Type 3 vWD
14.2.4. Acquired vWD
14.3. Market Value Forecast, by Drug, 2017–2027
14.3.1. Desmopressin
14.3.2. Clot-stabilizing Medications
14.3.3. Replacement Therapies
14.3.4. Contraceptives
14.3.5. Others
14.4. Market Value Forecast, by Route of Administration, 2017–2027
14.4.1. Oral
14.4.2. Injection
14.4.3. Other
14.5. Market Value Forecast, by Gender, 2017–2027
14.5.1. Men
14.5.2. Women
14.6. Market Value Forecast, by Distribution Channel, 2017–2027
14.6.1. Online Pharmacies
14.6.2. Retail Pharmacies
14.6.3. Hospital Pharmacies
14.7. Market Value Forecast, by Country/Sub-region, 2017–2027
14.7.1. China
14.7.2. India
14.7.3. Japan
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Disease Type
14.8.2. By Drug
14.8.3. By Route of Administration
14.8.4. By Gender
14.8.5. By Distribution Channel
14.8.6. By Country/Sub-region
15. Latin America von Willebrand Disease Treatment Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Disease Type, 2017–2027
15.2.1. Type 1 vWD
15.2.2. Type 2 vWD
15.2.3. Type 3 vWD
15.2.4. Acquired vWD
15.3. Market Value Forecast, by Drug, 2017–2027
15.3.1. Desmopressin
15.3.2. Clot-stabilizing Medications
15.3.3. Replacement Therapies
15.3.4. Contraceptives
15.3.5. Others
15.4. Market Value Forecast, by Route of Administration, 2017–2027
15.4.1. Oral
15.4.2. Injection
15.4.3. Other
15.5. Market Value Forecast, by Gender, 2017–2027
15.5.1. Men
15.5.2. Women
15.6. Market Value Forecast, by Distribution Channel, 2017–2027
15.6.1. Online Pharmacies
15.6.2. Retail Pharmacies
15.6.3. Hospital Pharmacies
15.7. Market Value Forecast, by Country/Sub-region, 2017–2027
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Disease Type
15.8.2. By Drug
15.8.3. By Route of Administration
15.8.4. By Gender
15.8.5. By Distribution Channel
15.8.6. By Country/Sub-region
16. Middle East & Africa von Willebrand Disease Treatment Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Disease Type, 2017–2027
16.2.1. Type 1 vWD
16.2.2. Type 2 vWD
16.2.3. Type 3 vWD
16.2.4. Acquired vWD
16.3. Market Value Forecast, by Drug, 2017–2027
16.3.1. Desmopressin
16.3.2. Clot-stabilizing Medications
16.3.3. Replacement Therapies
16.3.4. Contraceptives
16.3.5. Others
16.4. Market Value Forecast, by Route of Administration, 2017–2027
16.4.1. Oral
16.4.2. Injection
16.4.3. Other
16.5. Market Value Forecast, by Gender, 2017–2027
16.5.1. Men
16.5.2. Women
16.6. Market Value Forecast, by Distribution Channel, 2017–2027
16.6.1. Online Pharmacies
16.6.2. Retail Pharmacies
16.6.3. Hospital Pharmacies
16.7. Market Value Forecast, by Country/Sub-region, 2017–2027
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Disease Type
16.8.2. By Drug
16.8.3. By Route of Administration
16.8.4. By Gender
16.8.5. By Distribution Channel
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (by Tier and Size of companies)
17.2. Market Share Analysis by Company (2018)
17.3. Company Profiles
17.3.1. Octapharma AG
17.3.1.1. Company Overview
17.3.1.2. Product Portfolio
17.3.1.3. SWOT Analysis
17.3.1.4. Strategic Overview
17.3.2. Grifols, S.A.
17.3.2.1. Company Overview
17.3.2.2. Product Portfolio
17.3.2.3. SWOT Analysis
17.3.2.4. Strategic Overview
17.3.3. Shire plc
17.3.3.1. Company Overview
17.3.3.2. Product Portfolio
17.3.3.3. SWOT Analysis
17.3.3.4. Strategic Overview
17.3.4. Baxter
17.3.4.1. Company Overview
17.3.4.2. Product Portfolio
17.3.4.3. SWOT Analysis
17.3.4.4. Strategic Overview
17.3.5. Novo Nordisk A/S
17.3.5.1. Company Overview
17.3.5.2. Product Portfolio
17.3.5.3. SWOT Analysis
17.3.5.4. Strategic Overview
17.3.6. Bayer AG
17.3.6.1. Company Overview
17.3.6.2. Product Portfolio
17.3.6.3. SWOT Analysis
17.3.6.4. Strategic Overview
17.3.7. Sanofi, Kedrion S.p.A
17.3.7.1. Company Overview
17.3.7.2. Product Portfolio
17.3.7.3. SWOT Analysis
17.3.7.4. Strategic Overview
17.3.8. CSL Behring
17.3.8.1. Company Overview
17.3.8.2. Product Portfolio
17.3.8.3. SWOT Analysis
17.3.8.4. Strategic Overview
17.3.9. Pfizer, Inc.
17.3.9.1. Company Overview
17.3.9.2. Product Portfolio
17.3.9.3. SWOT Analysis
17.3.9.4. Strategic Overview
17.3.10. Ferring B.V.
17.3.10.1. Company Overview
17.3.10.2. Product Portfolio
17.3.10.3. SWOT Analysis
17.3.10.4. Strategic Overview
17.3.11. Other Prominent Players

List of Tables

Table 01: Key Mergers & Acquisition in the von Willebrand Disease Treatment Market
Table 02: Global von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2017–2027
Table 03: Global von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Drug, 2017–2027
Table 04: Global von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 05: Global von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Gender, 2017–2027
Table 06: Global von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 07: Global von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Region, 2017–2027
Table 08: North America von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Country, 2017–2027
Table 09: North America von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2017–2027
Table 10: North America von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Drug, 2017–2027
Table 11: North America von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 12: North America von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Gender, 2017–2027
Table 13: North America von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 14: Europe von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 15: Europe von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2017–2027
Table 16: Europe von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Drug, 2017–2027
Table 17: Europe von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 18: Europe von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Gender, 2017–2027
Table 19: Europe von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 20: Asia Pacific von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 21: Asia Pacific von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2017–2027
Table 22: Asia Pacific von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Drug, 2017–2027
Table 23: Asia Pacific von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 24: Asia Pacific von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Gender, 2017–2027
Table 25: Asia Pacific von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 26: Latin America von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 27: Latin America von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2017–2027
Table 28: Latin America von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Drug, 2017–2027
Table 29: Latin America von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 30: Latin America von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Gender, 2017–2027
Table 31: Latin America von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 32: Middle East & Africa von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 33: Middle East & Africa von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2017–2027
Table 34: Middle East & Africa von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Drug, 2017–2027
Table 35: Middle East & Africa von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 36: Middle East & Africa von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Gender, 2017–2027
Table 37: Middle East & Africa von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2027


• 英文レポート名:von Willebrand Disease Treatment Market (Disease Type: Type 1 von Willebrand Disease, Type 2 von Willebrand Disease, Type 3 von Willebrand Disease, and Acquired von Willebrand Disease; Drug: Desmopressin, Clot-stabilizing Medications, Replacement Therapies, Contraceptives, and Others; Route of Administration: Oral, Injection, and Other; Gender: Men and Women; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027
• 日本語訳:フォンビルブランド病治療の世界市場
• レポートコード:TPM-AG026お問い合わせ(見積依頼・ご注文・質問)